Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1993-3-15
|
| pubmed:abstractText |
DEODAN is a lysozyme lysate from Lactobacillus bulgaricus for oral administration which has shown antitumor activity in mice and humans. The effects of this preparation on some functions of monocytes/macrophages and on host resistance to experimental infections were examined. The oral administration to mice of DEODAN-150 mg/kg daily (the recommended dose in humans) caused an increase of the spreading ability and phagocytic activity of peritoneal macrophages, which showed morphological signs of cell activation. The level of Interleukin-1 (IL-1) secreted in the culture supernatant of peritoneal macrophages of DEODAN-treated mice was found to be slightly increased only when the mice were treated with 150 mg/kg DEODAN for 10 days. However, the in vitro incubation of human blood monocytes with DEODAN resulted in induction of membrane-bound and cytoplasmic IL-1 and Tumor Necrosis Factor (TNF)-alpha. The oral treatment of mice with DEODAN also caused a decrease in mortality after experimental infections with Klebsiella pneumoniae and Listeria monocytogenes. These results indicate that DEODAN activates the phagocytic and secretory functions of mononuclear cells and increases host resistance to bacterial infections.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Bacterial Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0192-0561
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
15
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
25-37
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:8432622-Adjuvants, Immunologic,
pubmed-meshheading:8432622-Administration, Oral,
pubmed-meshheading:8432622-Animals,
pubmed-meshheading:8432622-Antineoplastic Agents,
pubmed-meshheading:8432622-Bacterial Infections,
pubmed-meshheading:8432622-Bacterial Proteins,
pubmed-meshheading:8432622-Immunity, Innate,
pubmed-meshheading:8432622-Interleukin-1,
pubmed-meshheading:8432622-Lactobacillus,
pubmed-meshheading:8432622-Leukocyte Count,
pubmed-meshheading:8432622-Macrophages,
pubmed-meshheading:8432622-Male,
pubmed-meshheading:8432622-Mice,
pubmed-meshheading:8432622-Mice, Inbred BALB C,
pubmed-meshheading:8432622-Mice, Inbred ICR,
pubmed-meshheading:8432622-Monocytes,
pubmed-meshheading:8432622-Peritoneal Cavity,
pubmed-meshheading:8432622-Phagocytosis,
pubmed-meshheading:8432622-Tumor Necrosis Factor-alpha
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Stimulating effect of DEODAN (an oral preparation from Lactobacillus bulgaricus "LB51") on monocytes/macrophages and host resistance to experimental infections.
|
| pubmed:affiliation |
Institute for State Control of Drugs, Sofia, Bulgaria.
|
| pubmed:publicationType |
Journal Article
|